Abstract:Human cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme responsible for the metabolism of similar to 50% of clinically used drugs and is often involved in drug drug interactions. It exhibits atypical binding and kinetic behavior toward many ligands. Binding of ligands to CYP3A4 is a complex process. Recent studies from both crystallography and biochemistry suggested the existence of a peripheral ligand-binding site at the enzyme surface. However, the stability of the ligand bound at this peripheral site and the possibility of discovering new CYP3A4 ligands based on this site remain unclear. In this study, we employed a combination of molecular docking, multiparalleled molecular dynamics (MD) simulations, virtual screening, and experimental bioassay to investigate these issues. Our results revealed that the binding mode of progesterone (PGS), a substrate of CYP3A4, in the crystal structure was not stable and underwent a significant conformational change. Through Glide docking and MD refinement, it was found that PGS was able to stably bind at the peripheral site via contacts with Phe215, Phe219, Phe220, and Asp214. On the basis of the refined peripheral site, virtual screening was then performed against the Enamine database. A total of three compounds were finally found to have inhibitory activity against CYP3A4 in both human liver microsome and recombinant human CYP3A4 enzyme assays, one of which showed potent inhibitory activity with IC50 lower than 1 mu M and two of which exhibited moderate inhibitory activity with IC50 values lower than 10 mu M. The findings not only presented the dynamic behavior of PGS at the peripheral site but also demonstrated the first indication of discovering CYP3A4 inhibitors based on the peripheral site.

Molecular Docking and Competitive Binding Study Discovered Different Binding Modes of Microsomal Prostaglandin E Synthase-1 Inhibitors

Discovery of Highly Potent Microsomal Prostaglandin E-2 Synthase 1 Inhibitors Using the Active Conformation Structural Model and Virtual Screen

Microsomal prostaglandin E synthase-1 exhibits one-third-of-the-sites reactivity.

Investigation into Potent Inflammation Inhibitors from Traditional Chinese Medicine

Single Hormone or Synthetic Agonist Induces Gs/Gi Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths.

Microsomal prostaglandin E2 synthase-1 and its inhibitors: Molecular mechanisms and therapeutic significance

Targeting Microsomal Prostaglandin E Synthase 1 to Develop Drugs Treating the Inflammatory Diseases.

Drug Design for Mpges-1 from Traditional Chinese Medicine Database: A Screening, Docking, Qsar, Molecular Dynamics, and Pharmacophore Mapping Study

Computer-Aided Drug Design of Anti-inflammatory Agents Targeting Microsomal Prostaglandin E2 Synthase-1 (mPGES-1)

Structural Insights into Selective and Dual Antagonism of EP2 and EP4 Prostaglandin Receptors

Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E<sub>2</sub> receptor EP2 subtype

Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping

Competitive Enzymatic Interactions Determine the Relative Amounts of Prostaglandins E2 and D2

An Update of Microsomal Prostaglandin E Synthase-1 and PGE2Receptors in Cardiovascular Health and Diseases

Structural Insights into Novel 15-Prostaglandin Dehydrogenase Inhibitors

Computer-Aided Designing Peptide Inhibitors of Human Hematopoietic Prostaglandin D2 Synthase Combined Molecular Docking and Molecular Dynamics Simulation

Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib

Myeloid Cell Microsomal Prostaglandin E Synthase-1 Fosters Atherogenesis in Mice

Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.

Structural and dynamic insights into substrate binding and catalysis of human lipocalin prostaglandin D synthase

Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2